María-Carlota Londoño1, Lara Neves Souza2, Juan-José Lozano3, Rosa Miquel2, Juan G Abraldes4, Laura-Patricia Llovet1, Alberto Quaglia2, Antoni Rimola1, Miquel Navasa1, Alberto Sánchez-Fueyo5. 1. Liver Unit, Hospital Clínic Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain. 2. Institute of Liver Studies, King's College Hospital, MRC Transplant Centre, King's College London University, London, England, United Kingdom. 3. Bioinformatic Platform, Biomedical Research Center in Hepatic and Digestive Diseases (CIBEREHD), Instituto de Salud Carlos III, Spain. 4. Cirrhosis Care Clinic, Liver Unit, Division of Gastroenterology, Centre of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, Canada. 5. Institute of Liver Studies, King's College Hospital, MRC Transplant Centre, King's College London University, London, England, United Kingdom. Electronic address: sanchez_fueyo@kcl.ac.uk.
Abstract
BACKGROUND & AIMS: Subclinical inflammatory changes are commonly described in long-term transplant recipients undergoing protocol liver biopsies. The pathogenesis of these lesions remains unclear. The aim of this study was to identify the key molecular pathways driving progressive subclinical inflammatory liver allograft damage. METHODS: All liver recipients followed at Hospital Clínic Barcelona who were >10 years post-transplant were screened for participation in the study. Patients with recurrence of underlying liver disease, biliary or vascular complications, chronic rejection, and abnormal liver function tests were excluded. Sixty-seven patients agreed to participate and underwent blood and serological tests, transient elastography and a liver biopsy. Transcriptome profiling was performed on RNA extracted from 49 out of the 67 biopsies employing a whole genome next generation sequencing platform. Patients were followed for a median of 6.8 years following the index liver biopsy. RESULTS: Median time since transplantation to liver biopsy was 13 years (10-22). The most frequently observed histological abnormality was portal inflammation with different degrees of fibrosis, present in 45 biopsies (67%). Two modules of 102 and 425 co-expressed genes were significantly correlated with portal inflammation, interface hepatitis and portal fibrosis. These modules were enriched in molecular pathways known to be associated with T cell mediated rejection. Liver allografts showing the highest expression levels for the two modules recapitulated the transcriptional profile of biopsies with clinically apparent rejection and developed progressive damage over time, as assessed by non-invasive markers of fibrosis. CONCLUSIONS: A large proportion of adult liver transplant recipients who survive long-term exhibit subclinical histological abnormalities. The transcriptomic profile of these patients' liver tissue closely resembles that of T cell mediated rejection and may result in progressive allograft damage. LAY SUMMARY: A large proportion of adult liver transplant recipients who survive for a long time exhibit subclinical histological abnormalities. The expression profile (a measurement of the activity of genes) of liver tissue from a large fraction of these patients closely resembles the profile of T cell mediated rejection. Liver allografts showing the highest expression levels of rejection-related genes developed progressive damage over time.
BACKGROUND & AIMS: Subclinical inflammatory changes are commonly described in long-term transplant recipients undergoing protocol liver biopsies. The pathogenesis of these lesions remains unclear. The aim of this study was to identify the key molecular pathways driving progressive subclinical inflammatory liver allograft damage. METHODS: All liver recipients followed at Hospital Clínic Barcelona who were >10 years post-transplant were screened for participation in the study. Patients with recurrence of underlying liver disease, biliary or vascular complications, chronic rejection, and abnormal liver function tests were excluded. Sixty-seven patients agreed to participate and underwent blood and serological tests, transient elastography and a liver biopsy. Transcriptome profiling was performed on RNA extracted from 49 out of the 67 biopsies employing a whole genome next generation sequencing platform. Patients were followed for a median of 6.8 years following the index liver biopsy. RESULTS: Median time since transplantation to liver biopsy was 13 years (10-22). The most frequently observed histological abnormality was portal inflammation with different degrees of fibrosis, present in 45 biopsies (67%). Two modules of 102 and 425 co-expressed genes were significantly correlated with portal inflammation, interface hepatitis and portal fibrosis. These modules were enriched in molecular pathways known to be associated with T cell mediated rejection. Liver allografts showing the highest expression levels for the two modules recapitulated the transcriptional profile of biopsies with clinically apparent rejection and developed progressive damage over time, as assessed by non-invasive markers of fibrosis. CONCLUSIONS: A large proportion of adult liver transplant recipients who survive long-term exhibit subclinical histological abnormalities. The transcriptomic profile of these patients' liver tissue closely resembles that of T cell mediated rejection and may result in progressive allograft damage. LAY SUMMARY: A large proportion of adult liver transplant recipients who survive for a long time exhibit subclinical histological abnormalities. The expression profile (a measurement of the activity of genes) of liver tissue from a large fraction of these patients closely resembles the profile of T cell mediated rejection. Liver allografts showing the highest expression levels of rejection-related genes developed progressive damage over time.
Authors: Safak Gül-Klein; Anika Kästner; Philipp Konstantin Haber; Felix Krenzien; Simon Wabitsch; Alexander Krannich; Andreas Andreou; Dennis Eurich; Frank Tacke; David Horst; Johann Pratschke; Moritz Schmelzle Journal: J Hepatocell Carcinoma Date: 2021-03-18
Authors: Olga Millán; Pablo Ruiz; Lara Orts; Paula Ferré; Gonzalo Crespo; Miguel Santana; Virginia Fortuna; Luís Quintairos; Miguel Navasa; Mercè Brunet Journal: Front Immunol Date: 2019-04-24 Impact factor: 7.561
Authors: Mylarappa Ningappa; Syed A Rahman; Brandon W Higgs; Chethan S Ashokkumar; Nidhi Sahni; Rakesh Sindhi; Jishnu Das Journal: Cell Rep Med Date: 2022-04-19
Authors: Michael Mengel; Alexandre Loupy; Mark Haas; Candice Roufosse; Maarten Naesens; Enver Akalin; Marian C Clahsen-van Groningen; Jessy Dagobert; Anthony J Demetris; Jean-Paul Duong van Huyen; Juliette Gueguen; Fadi Issa; Blaise Robin; Ivy Rosales; Jan H Von der Thüsen; Alberto Sanchez-Fueyo; Rex N Smith; Kathryn Wood; Benjamin Adam; Robert B Colvin Journal: Am J Transplant Date: 2020-06-27 Impact factor: 9.369
Authors: Anne Höfer; Danny Jonigk; Björn Hartleben; Murielle Verboom; Michael Hallensleben; Michael P Manns; Elmar Jaeckel; Richard Taubert Journal: Sci Rep Date: 2020-08-28 Impact factor: 4.379
Authors: Safak Gül-Klein; Henriette Hegermann; Robert Röhle; Moritz Schmelzle; Frank Tacke; Wenzel Schöning; Robert Öllinger; Tomasz Dziodzio; Patrick Maier; Julius M Plewe; David Horst; Igor Maximilian Sauer; Johann Pratschke; Nils Lachmann; Dennis Eurich Journal: J Inflamm Res Date: 2021-06-23